Royalty Pharma

Royalty Pharma Plc provides drug development services. The firm operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Royalty Pharma reports robust Q4 performance and strategic growth outlook

Royalty Pharma's Q4 2022 earnings call highlighted strong financial performance, efficient cash flow management, and strategic acquisitions. While facing challenges in certain product sales trajectories and market conditions, the company remains focused on innovation and long-term success in the life sciences industry.

Royalty Pharma reports robust Q1 performance and raises capital deployment guidance

Royalty Pharma's Q1 2023 earnings call highlighted strong financial performance, strategic portfolio expansion, and disciplined capital deployment. The company's robust financial health, selective investment approach, and optimistic outlook on market opportunities position them for continued growth. Challenges in deal flow prediction and balancing investments underscore the need for strategic planning and adaptability in a competitive market landscape.

Royalty Pharma (RPRX) reports robust Q2 results amidst regulatory challenges

Royalty Pharma's Q2 performance reflects resilience and growth, supported by strategic initiatives and strong financial metrics. While facing challenges related to regulatory impacts and investor sentiment, the company is focused on leveraging opportunities in attracting investors, educating about its business model, and expanding capital deployment for future growth.

Royalty Pharma reports robust Q3 performance and optimistic growth outlook

Royalty Pharma's Q3 earnings call showcased strong financial performance, active capital allocation, and a focus on shareholder value creation. The company's robust financial model, emphasis on tailored solutions, and optimism about portfolio growth position it well for future opportunities.

Royalty Pharma reports robust 2023 performance and outlines growth strategies

Royalty Pharma's strong performance in 2023 and strategic acquisitions position the company for continued growth in 2024.
Challenges include legal uncertainties and managing shareholder turnover, while opportunities exist in innovative investments and enhanced investor relations.
The company's focus on transparency and attracting long-term investors underscores its commitment to sustainable growth.

Royalty Pharma reports strong Q1 growth and strategic acquisitions

Royalty Pharma's Q1 performance reflects growth and strategic acquisitions, positioning the company for future success.
While facing challenges related to safety concerns and short-term portfolio fluctuations, Royalty Pharma remains focused on growth.
The company's emphasis on identifying high-potential drugs and upcoming milestones underscores a promising outlook for investors.

Royalty Pharma reports robust Q3 growth and eyes innovative therapies

Royalty Pharma's Q3 performance reflects strong growth and strategic decision-making, positioning the company for continued success.
Despite challenges in market penetration and administration, Royalty Pharma remains optimistic about its growth prospects and innovative therapies.
The company's focus on synthetic royalties, strategic acquisitions, and financial discipline underpin its resilience and potential for future expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Apple

Occidental Petroleum

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Ally Financial

Activision Blizzard

Chevron

General Motors

Kroger

U.S. Bancorp

Warren Buffett (Trades, Portfolio)'s multibillion-dollar conglomerate, Berkshire Hathaway Inc. ( BRK.A , Financial)( BRK.B , Financial), disclosed its equity portfolio for the second quarter of 2022 on Monday.

Warren Buffett Ramps Up Occidental and Apple Stakes, Dumps Verizon

Warren Buffett's Berkshire Hathaway Inc on Monday said it more than tripled its stake in the online banking company Ally Financial Inc, while shedding its stakes in Verizon Communications Inc and Royalty Pharma Plc, which buys drug royalties.

Buffett's Berkshire more than triples Ally stake, sheds Verizon

Theravance Biopharma

Highest quarter of YUPELRI® (revefenacin) net sales and profitability to date 1 : $17.2M Q2 2022 sales up 17% from Q2 2021 (implied 35% share) Ampreloxetine discussions with FDA create a path to NDA filing with one additional Phase 3 clinical study in Multiple System Atrophy (MSA) patients with symptomatic neurogenic orthostatic hypotension (nOH) Closed transaction to sell TRELEGY ELLIPTA royalty interests to Royalty Pharma for approximately $1.1 billion in upfront cash with over $1.5 billion in total potential value Launched tender offer for outstanding 3.25% Convertible Senior Notes  DUBLIN , Aug. 4, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the second quarter of 2022. "The Company has continued to execute on its strategy and, since the first quarter, we have accomplished several transformative goals.

Theravance Biopharma, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

Royalty Pharma plc (NASDAQ:RPRX ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants George Grofik - SVP, Head, IR & Communications Pablo Legorreta - Founder & CEO Marshall Urist - EVP & Head, Research & Investments Terry Coyne – EVP & CFO Chris Hite - Vice Chairman Conference Call Participants Chris Shibutani - Goldman Sachs Chris Schott - J.P. Morgan Terence Flynn - Morgan Stanley Andrew Baum - Citi Steven Scala - Cowen Geoff Meacham - Bank of America Mike DiFiore - Evercore Ash Verma - UBS Operator Ladies and gentlemen, thank you for standing by.

Royalty Pharma's (RPRX) CEO Pablo Legorreta on Q2 2022 Results - Earnings Call Transcript

NEW YORK, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2022 and raised full-year 2022 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial measure).

Royalty Pharma Reports Second Quarter 2022 Results

Blueprint Medicines

-- Achieved $36.5 million in total revenues, including $28.5 million in AYVAKIT® (avapritinib) net product revenues representing 20 percent AYVAKIT revenue growth from Q1 2022 -- -- Plan to report topline data for registration-enabling PIONEER trial of AYVAKIT in non-advanced SM in August 2022 -- -- Licensed KIT exon 13 inhibitor to IDRx in exchange for a 15 percent Series A preferred equity investment, and the potential to receive up to $217.5 million in development, regulatory, and sales-based milestones and tiered percentage royalties -- -- Investor Day planned for November 1, 2022 in New York, NY -- CAMBRIDGE, Mass. , Aug. 2, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the second quarter ended June 30, 2022.

Blueprint Medicines Reports Second Quarter 2022 Results

NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2022 of $0.19 per Class A ordinary share.

Royalty Pharma Declares Third Quarter 2022 Dividend

Shares of Theravance Biopharma Inc. TBPH, -0.80% were up 13.8% in premarket trading on Thursday, the day after the company announced plans to sell the royalty rights to GlaxoSmithKline's GSK, -1.25% Trelegy Ellipta to Royalty Pharma RPRX, -0.40% for $1.1 billion in cash and up to $450 million in potential milestone payments. Trelegy Ellipta is a treatment for asthma and chronic obstructive pulmonary disease.

Theravance sets up deal to sell rights to asthma drug to Royalty Pharma

Innoviva

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that the company has entered into an agreement to sell its 15% economic stake in Theravance Respiratory Company LLC (“TRC”), which receives royalties stemming from sales of TRELEGY® ELLIPTA®, to Royalty Pharma plc (Nasdaq: RPRX) for an upfront cash payment of approximately $282 millio

Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million plus full ownership of existing equity investments and the potential for $50 million milestone payment

NEW YORK, July 13, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has agreed to acquire a royalty interest in TRELEGY ELLIPTA (Trelegy) from Theravance Biopharma, Inc. (Nasdaq: TBPH) and Innoviva, Inc. (Nasdaq: INVA) for $1.31 billion in cash up front and up to $300 million in additional payments contingent on the achievement of certain sales milestones. The acquisition is expected to close within ten business days.

Royalty Pharma Agrees to Acquire Royalty Interest in TRELEGY ELLIPTA From Theravance and Innoviva for $1.31 Billion and Potential Milestones of $300 Million

Over $1.5 Billion in Potential Total Value, Including Approximately $1.1 Billion in Upfront Cash, up to $250 Million in Sales-Based Milestone Payments and an Estimated NPV Approximately $200 Million of Rights to TRELEGY ELLIPTA Outer Year Royalties1 Royalty Pharma to Invest up to $40 Million to Advance Development of Ampreloxetine in Multiple System Atrophy (MSA) in Exchange for Unsecured Low Single-Digit Royalties Theravance Biopharma to Hold a Conference Call Today at 5 pm ET / 2 pm PT / 10 pm IST DUBLIN , July 13, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced it has entered into a definitive agreement to sell all of its units in Theravance Respiratory Company, LLC representing its 85% economic interest in the sales-based royalty rights on worldwide net sales of GSK's TRELEGY ELLIPTA ("TRELEGY") to Royalty Pharma (NASDAQ: RPRX) for over $1.5 billion in potential total value (the "TRELEGY Royalty Transaction"). The transaction is intended to provide near-, mid- and long-term value to the Company with an upfront cash payment of approximately $1.1 billion, up to $250 million in additional milestone payments contingent on the achievement of certain TRELEGY net sales thresholds between 2023 and 2026 and outer year royalties to the Company providing an opportunity to receive an estimated NPV of approximately $200 million.1 Immediately after announcing the TRELEGY Royalty Transaction, Theravance Biopharma intends to initiate a multi-step process to eliminate its outstanding debt and return capital to shareholders.

Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total Value

Shares of Blueprint Medicines Corp. BPMC, -2.34% gained 3.3% in premarket trading on Thursday after the company announced a deal with investment firm Sixth Street and Royalty Pharma RPRX, -1.10% , which acquires pharmaceutical royalties, worth up to $1.2 billion. Sixth Street will pay $250 million upfront for future royalties for two products, up to $400 million in a senior secured credit facility, and $260 million in a potential credit facility to support any buy-side business opportunities.

Blueprint inks deal with Sixth Street, Royalty Pharma worth up to $1.2 billion

NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired an ex-U.S. royalty interest in Gavreto (pralsetinib) from Blueprint Medicines (Nasdaq: BPMC) for up to $340 million, consisting of $175 million upfront and up to $165 million in potential sales-based milestones.

Royalty Pharma Acquires Royalty Interest in Gavreto From Blueprint Medicines for up to $340 Million

Strengthens balance sheet with significant non-dilutive, low-cost capital Expands ability to bring the promise of precision therapy to broad patient populations through internal R&D and strategic business development Propelled by global launches of AYVAKIT®/AYVAKYT® (avapritinib) and GAVRETO® (pralsetinib), and shared confidence in the important growth opportunity in systemic mastocytosis Blueprint Medicines will receive $575 million in total cash funded at close CAMBRIDGE, Mass. , June 30, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced strategic financing collaborations with Sixth Street and Royalty Pharma (NASDAQ: RPRX) for up to $1.25 billion, bringing significant non-dilutive, low-cost capital to drive innovation and growth.

Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma

Royalty Pharma (RPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Royalty Pharma (RPRX) Surges 5.2%: Is This an Indication of Further Gains?

AbbVie

Bristol-Myers

Wells Fargo

One of Berkshire Hathaway's longest-held stocks was given the heave-ho in the first quarter.

5 Stocks Warren Buffett Has Aggressively Sold Since 2022 Began

NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022 at 2:20 p.m. ET.

Royalty Pharma to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

Royalty Pharma lets you diversify within the healthcare sector. A bear market is actually conducive to its business model.

Royalty Pharma: Unique Diversification, Bear Market Performer

NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the UBS Global Healthcare Conference 2022 on May 24, 2022 at 1:15 p.m. ET.

Royalty Pharma to Present at the UBS Global Healthcare Conference 2022

Citigroup

Celanese

Floor & Decor Holdings

Liberty Media Corp-Liberty Formula One

McKesson

Markel

Microsoft

Paramount Global

STORE Capital

Synchrony Financial

The Oracle of Omaha was very active in the markets.

Here's Every Stock Warren Buffett Bought or Sold in the First Quarter

Royalty Pharma plc (NASDAQ:RPRX ) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Company Participants George Grofik - Senior Vice President, Head-Investor Relations & Communications Terry Coyne - Executive Vice President & Chief Financial Officer Marshall Urist - Head, Research & Investments Chris Hite - Vice Chairman Conference Call Participants Chris Schott - JPMorgan Terence Flynn - Morgan Stanley Chris Shibutani - Goldman Sachs Geoff Meacham - Bank of America Umer Raffat - Evercore Andrew Baum - Citi Greg Fraser - Truist Securities Steve Scala - Cowen Operator Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma First Quarter Earnings Conference Call.

Royalty Pharma plc (RPRX) Management on Q1 2022 Results - Earnings Call Transcript

Royalty Pharma (RPRX) delivered earnings and revenue surprises of -15.28% and 3.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Royalty Pharma (RPRX) Lags Q1 Earnings Estimates

NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2022 and reaffirmed full-year 2022 guidance for Adjusted Cash Receipts(1) (a non-GAAP financial measure).

Royalty Pharma Reports First Quarter 2022 Results

NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) --  The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2022 of $0.19 per Class A ordinary share.

Royalty Pharma Declares Second Quarter 2022 Dividend

NEW YORK, April 13, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2022 financial results on Thursday, May 5, 2022 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

News for Royalty Pharma Stock (RPRX)